ArticleFrontiers in tuberculosis2024
Serum-derived host miR-423-5p and miR-378a-3p as molecular markers for severe tuberculosis: a promising prognostic tool for survival.
Article in Frontiers in tuberculosis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Type 2 diabetes mellitus associated microRNAs in tuberculosis susceptibility: a systematic review and bioinformatic analysis.Frontiers in endocrinology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) remains a leading cause of infectious disease-related mortality. Annually, 10 million people contract TB, resulting in 1.5 million deaths, despite being a preventable and curable disease. Severe TB cases necessitate Intensive Care Unit (ICU) admission, with mortality rates ranging from 15.5 to 65.9%. Recent research highlights the role of microRNAs (miRNAs) in infectious disease diagnosis, with studies reporting distinct miRNA profiles in active pulmonary TB and sputum samples. This study aims to identify miRNAs as potential prognostic biomarkers for severe TB in ICU patients. Total RNA was extracted from the serum of ICU TB patients and controls. miRNA libraries were prepared and high throughput sequenced using a MiSeq Illumina platform. Differential miRNA abundance between patients and controls was analyzed with sRNAtoolbox, and DESeq2 was used for comparisons. Results demonstrated three differentially abundant miRNAs in severe TB patients' serum, validated by RT-qPCR. Stratifying patients by outcome revealed a significant difference in the ratio between two miRNAs: hsa-miR-378a-3p and hsa-miR-423-5p. The analysis showed that a miRNA-423-5p/miRNA-378a-3p ratio < 27 is associated with a poor prognosis, highlighting its potential as a prognostic indicator of disease severity. These findings are promising and warrant validation, while assessing these biomarkers in non-severe TB settings could further help identify more aggressive forms of the disease. In conclusion, this study explores the potential of circulating miRNAs as prognostic tools for severe TB cases in the ICU, offering a promising avenue for improving clinical decision-making and patient outcomes. Further validation and exploration in diverse TB contexts are essential for comprehensive understanding and application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.